Key clinical point: A majority of patients with metastatic breast cancer (BC) who received alpelisib developed hyperglycemia of any grade, with alpelisib-associated hyperglycemia being more prevalent in standard clinical practice than in clinical trials.
Major finding: Overall, 61.5% of patients developed any-grade hyperglycemia, with the rate being considerably higher in patients who received alpelisib as part of standard care vs clinical trial (80.3% vs 34.0%). Baseline body mass index ≥ 25 kg/m2 (P = .036) and A1c levels in the prediabetes and diabetes range (P < .001) were significantly associated with the development of any-grade hyperglycemia.
Study details: Findings are from a retrospective cohort study including 247 patients with metastatic BC who received alpelisib either as standard care (n = 147) or in a clinical trial setting (n = 100).
Disclosures: This work was supported partly by the US National Institutes of Health/National Cancer Institute. Some authors declared receiving honoraria, research funding, or consultant fees from some sources.
Source: Shen S et al. Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer. Cancer. 2023 (Sep 25). doi: 10.1002/cncr.34928